Videos

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the key takeaways of this year's keynote speech. 

Access Insights 2024: Financial Headwinds and Tailwinds to Commercialization

Articles

Session dives into how healthcare policy implementation impacts stakeholders long-term.  

Access Insights 2024: Practicing Proactivity by Mapping Out Future Chessboard Moves

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses other standout sessions at this year’s Access Insights conference.

Access Insights 2024: Notable Breakout Sessions

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena. 

Access Insights 2024: Analyzing Drug Pricing and Reimbursement Data Amid a New Wave of CMS Price Requirements 

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses breakout session and the impact of healthcare policies on manufacturing and commercialization. 

Access Insights 2024: Playing the Chess Endgame: Healthcare Policies Targeting Drug Commercialization

The conference’s opening keynote sets the scene for 2025 and the years to come. 

Access Insights 2024: Commercialization’s Financial Headwinds and Tailwinds

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses examples of how effective communication can resolve supply chain issues. 

Effective Resolutions to Supply Chain Issues

The company’s annual edition reveals the latest numbers in the sector, including a rise in average employer-sponsored health insurance premiums for single and family coverage of 24% and 28% respectively. 

KFF Releases Results of Employer Health Benefits Survey

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses how to handle opposing concerns between supply chain teams and offers communication solutions. 

LogiPharma USA 2024: Confronting Conflicting Priorities Between Supply Chain Partners

The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.

News